Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MRC HIU scientists have isolated therapeutic antibodies from healthy volunteers exposed to the Ebola vaccine but not Ebola virus itself, suggesting that protective therapies could be developed from people who are disease-free.

The researchers say their findings could apply to other infectious diseases from MERS to SARS and avian influenza, paving the way to a fast and cost-effective approach to developing new antibody therapies. Their study was published in the journal Cell Reports.

The Ebola epidemic, ongoing in the Democratic Republic of Congo, resurfaced in West Africa in March 2014, quickly becoming the largest outbreak since it was first discovered in 1976. A worldwide effort to develop treatments has resulted in a handful of promising candidates, including antibody therapies to help treat those already infected.

MRC scientists considered whether blood samples taken from volunteers in vaccine trials could yield protective antibodies against Ebola. These samples are readily available from vaccine trial studies, though they have not until now been considered because of concerns that they may not have the same potential compared to antibodies taken from survivors’ blood.

Conventionally, antibodies intended for therapy are collected from individuals who have survived infection because the antibodies in their blood are seen as being more potent from prolonged exposure. However, blood samples from survivors can be difficult to obtain and may have risks, such as persistent viruses or other pathogens, tied to them.

The researchers isolated 82 antibodies taken from 11 healthy volunteers participating in an Ebola vaccine trial at the Jenner Institute in Oxford. Despite having less maturation time, the team noticed that one-third of all the antibodies isolated were effective at neutralising the Zaire species of Ebola, which is the basis of the vaccine. The scientists generated a ‘cocktail’ of four antibodies, resulting in a therapy which successfully cured six guinea pigs when it was administered on day three of infection.

Lead author, Professor Alain Townsend, of the MRC Human Immunology Unit, said: “A useful opportunity to uncover antibodies from healthy volunteers in vaccine trials is being missed. Presently, many experimental vaccines for life-threatening infections, such as H5N1 and H7N9 avian influenza to SARS and MERS, are entering clinical trials. We are strongly recommending that these trials include antibody isolation. It is a small, extra step that could lead to new antibody therapies from an increased pool of donors and with reduced risk.”

Dr Martin Broadstock, Programme Manager for Immunology at the MRC, said: “This new way of using existing vaccine trials could offer a speedy response to serious global infections, only requiring a small additional step in trial design, rather than relying on survivors of deadly infectious diseases.”

The researchers have sent their cocktail to scientists at the Public Health Agency of Canada, where it will be tested on two other species of Ebola (Bundibugyo and Sudan) that cause outbreaks in humans. Depending on the results, the antibodies could be available for clinical trials in humans. The researchers said they would also make their antibodies available to other developers to study whether a combination therapy may be more potent.

Similar stories

Spatial transcriptomics of neurodegeneration in Progressive Multiple Sclerosis (MS)

In a paper published in Nature Neuroscience, the Fugger Group describe molecular pathways of MS neurodegeneration in unprecedented detail.

Lister Research Prize Fellows Announced

James Davies has been named as one of eight researchers selected for the 2022 Fellowship scheme.

New Associate Professor titles conferred

Stephen Twigg and Adam Wilkinson have both been awarded Associate Professor titles in the most recent announcement from the Radcliffe Department of Medicine

Research shines at the MRC WIMM Post-doc Symposium

Held on 16th June 2022 at Somerville College in Oxford, the one-day event brought together post-doctoral researchers from across the Institute to share their research.

Understanding the interplay of dietary iron, anaemia and the immune system

Four related projects aim to unravel how the iron we eat shapes how the immune system develops and responds to vaccines.

MRC WIMM fundraising raises £583 for the British Red Cross

We are delighted to announced the result of fundraising efforts across the past few months.